NASDAQ:THOR - Thoratec Stock Price, Price Target & More

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Thoratec (NASDAQ:THOR)

Thoratec logoThoratec Corporation develops, manufactures and markets medical devices used for mechanical circulatory support for the treatment of heart failure patients. The Company's products include ventricular assist devices (VADs), such as HeartMate II Left Ventricular Assist System (HeartMate II), HeartMate III Left Ventricular Assist System, Thoratec Paracorporeal Ventricular Assist Device (PVAD) and Thoratec Implantable Ventricular Assist Device (IVAD). For acute circulatory support, the Company's product lines are CentriMag Acute Circulatory System (CentriMag) and for pediatric patients PediMag/PediVAS Acute Circulatory System (PediMag/PediVAS). HeartMate III, a centrifugal-flow, chronic, left ventricular assist system.

Receive THOR News and Ratings via Email

Sign-up to receive the latest news and ratings for THOR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Equipment


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins10.29%
Return on Equity8.02%
Return on Assets6.71%


Outstanding SharesN/A

How to Become a New Pot Stock Millionaire

Thoratec (NASDAQ:THOR) Frequently Asked Questions

What is Thoratec's stock symbol?

Thoratec trades on the NASDAQ under the ticker symbol "THOR."

How were Thoratec's earnings last quarter?

Thoratec Co. (NASDAQ:THOR) announced its quarterly earnings results on Tuesday, August, 4th. The medical instruments supplier reported $0.37 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.09. The medical instruments supplier earned $128.70 million during the quarter, compared to analysts' expectations of $115.48 million. Thoratec had a net margin of 10.29% and a return on equity of 8.02%. Thoratec's quarterly revenue was up 9.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.43 earnings per share. View Thoratec's Earnings History.

Has Thoratec been receiving favorable news coverage?

Headlines about THOR stock have trended somewhat positive on Wednesday, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Thoratec earned a media sentiment score of 0.10 on Accern's scale. They also gave news coverage about the medical instruments supplier an impact score of 44.95 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Thoratec?

Shares of THOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Thoratec?

Thoratec's mailing address is 6035 Stoneridge Dr, PLEASANTON, CA 94588, United States. The medical instruments supplier can be reached via phone at +1-925-8478600.

MarketBeat Community Rating for Thoratec (THOR)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  281 (Vote Outperform)
Underperform Votes:  288 (Vote Underperform)
Total Votes:  569
MarketBeat's community ratings are surveys of what our community members think about Thoratec and other stocks. Vote "Outperform" if you believe THOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe THOR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Thoratec (NASDAQ:THOR) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/25/2016 forward)


Thoratec (NASDAQ:THOR) Earnings History and Estimates Chart

Earnings by Quarter for Thoratec (NASDAQ:THOR)

Thoratec (NASDAQ THOR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2015Q215$0.28$0.37$115.48 million$128.70 millionViewListenView Earnings Details
5/7/2015Q115$0.26$0.38$111.10 million$121.31 millionViewListenView Earnings Details
2/10/2015Q414$0.24$0.39$106.90 million$127.96 millionViewListenView Earnings Details
11/5/2014Q314$0.22$0.18$106.30 million$105.80 millionViewListenView Earnings Details
8/6/2014Q214$0.43$0.43$128.30 million$118.10 millionViewListenView Earnings Details
5/6/2014Q114$0.39$0.41$122.56 million$125.70 millionViewListenView Earnings Details
2/4/2014Q413$0.41$0.38$128.47 million$128.20 millionViewListenView Earnings Details
10/30/2013Q313$0.40$0.49$121.25 million$126.40 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.43$0.52$121.51 million$130.50 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.46$0.41$122.53 million$117.73 millionViewListenView Earnings Details
2/5/2013Q4 2012$0.38$0.38$119.09 million$128.50 millionViewListenView Earnings Details
11/1/2012Q312$0.39$0.41$111.80 million$117.80 millionViewN/AView Earnings Details
8/1/2012$0.45$0.45ViewN/AView Earnings Details
5/1/2012$0.41$0.61ViewN/AView Earnings Details
2/8/2012Q4 2011$0.30$0.31ViewN/AView Earnings Details
11/1/2011$0.33$0.41ViewN/AView Earnings Details
8/3/2011$0.35$0.44ViewN/AView Earnings Details
5/3/2011$0.33$0.34ViewN/AView Earnings Details
1/27/2011$0.30$0.28ViewN/AView Earnings Details
10/28/2010Q3 2010$0.25$0.26ViewN/AView Earnings Details
7/29/2010Q2 2010$0.28$0.29ViewN/AView Earnings Details
4/29/2010Q1 2010$0.19$0.27ViewN/AView Earnings Details
1/28/2010Q4 2009$0.16$0.24ViewN/AView Earnings Details
11/4/2009Q3 2009$0.15$0.20ViewN/AView Earnings Details
8/5/2009Q2 2009$0.15$0.17ViewN/AView Earnings Details
5/7/2009Q1 2009$0.13$0.17ViewN/AView Earnings Details
2/5/2009Q4 2008$0.10$0.11ViewN/AView Earnings Details
10/30/2008Q3 2008$0.07$0.13ViewN/AView Earnings Details
7/31/2008Q2 2008$0.01$0.15ViewN/AView Earnings Details
5/1/2008Q1 2008$0.03$0.01ViewN/AView Earnings Details
2/5/2008Q4 2007$0.06$0.07ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Thoratec (NASDAQ:THOR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Thoratec (NASDAQ THOR) Insider Trading and Institutional Ownership History

Insider Trading History for Thoratec (NASDAQ:THOR)

Thoratec (NASDAQ THOR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/26/2015Neil F DimickDirectorSell8,173$44.98$367,621.54View SEC Filing  
5/15/2015Paul A LavioletteDirectorSell5,668$44.70$253,359.60View SEC Filing  
4/10/2015Neil F DimickDirectorSell4,786$43.00$205,798.00View SEC Filing  
12/4/2014J Daniel ColeDirectorSell5,000$31.83$159,150.00View SEC Filing  
5/27/2014Neil F DimickDirectorSell4,158$32.15$133,679.70View SEC Filing  
5/15/2014Paul LavioletteDirectorSell6,023$31.23$188,098.2919,299View SEC Filing  
3/10/2014Gerhard BurbachCEOSell22,104$36.53$807,459.12128,324View SEC Filing  
2/11/2014Gerhard BurbachCEOSell20,000$34.71$694,200.00156,307View SEC Filing  
1/15/2014Gerhard BurbachCEOSell9,400$38.10$358,140.00156,307View SEC Filing  
1/14/2014Gerhard BurbachCEOSell30,600$36.65$1,121,490.00156,307View SEC Filing  
12/10/2013Gerhard BurbachCEOSell40,000$38.15$1,526,000.00156,307View SEC Filing  
11/12/2013Gerhard BurbachCEOSell100,000$41.40$4,140,000.00156,307View SEC Filing  
10/28/2013Gerhard F BurbachCEOSell15,000$40.02$600,300.00View SEC Filing  
10/17/2013Gerhard F BurbachCEOSell9,600$39.00$374,400.00View SEC Filing  
10/14/2013Gerhard BurbachCEOSell40,400$38.17$1,542,068.00156,307View SEC Filing  
10/11/2013David Aaron LehmanSVPSell21,889$38.17$835,503.1343,077View SEC Filing  
5/28/2013Neil F DimickDirectorSell1,273$31.58$40,201.34View SEC Filing  
5/20/2013Neil F DimickDirectorSell1,250$31.61$39,512.50View SEC Filing  
5/13/2013Neil F DimickDirectorSell1,250$33.93$42,412.50View SEC Filing  
11/26/2012Gerhard F BurbachCEOSell11,600$38.09$441,844.00View SEC Filing  
10/4/2012David Aaron LehmanSVPSell12,300$36.11$444,153.00View SEC Filing  
(Data available from 1/1/2013 forward)


Thoratec (NASDAQ THOR) News Headlines

Financial Analysis: Cerner (CERN) & Thoratec (THOR)Financial Analysis: Cerner (CERN) & Thoratec (THOR) - February 28 at 9:16 PM
Financial Analysis: PerkinElmer (PKI) and Thoratec (THOR)Financial Analysis: PerkinElmer (PKI) and Thoratec (THOR) - December 27 at 3:54 PM
Analyzing Thoratec (THOR) & Waters (WAT)Analyzing Thoratec (THOR) & Waters (WAT) - December 11 at 9:30 PM
Top Funds' New Buys: GrubHub Delivers Food, ProfitTop Funds' New Buys: GrubHub Delivers Food, Profit - December 5 at 10:31 AM
Critical Contrast: Thoratec (THOR) & Waters (WAT)Critical Contrast: Thoratec (THOR) & Waters (WAT) - December 1 at 5:40 AM
EnteroMedics (ETRM) & Thoratec (THOR) Head-To-Head ReviewEnteroMedics (ETRM) & Thoratec (THOR) Head-To-Head Review - October 11 at 12:08 AM
Thoratec (THOR) & Biolase (BIOL) Critical AnalysisThoratec (THOR) & Biolase (BIOL) Critical Analysis - October 5 at 9:46 AM
Dont Buy RV Stocks As Hurricane PlaysDon't Buy RV Stocks As Hurricane Plays - September 7 at 9:54 AM
Reviewing Thoratec (THOR) & Intuitive Surgical (ISRG)Reviewing Thoratec (THOR) & Intuitive Surgical (ISRG) - August 20 at 2:28 PM
Head-To-Head Comparison: Accuray (ARAY) & Thoratec (NASDAQ:THOR)Head-To-Head Comparison: Accuray (ARAY) & Thoratec (NASDAQ:THOR) - July 4 at 8:25 AM
Thor Industries Stock Drops Double Digits on Mixed EarningsThor Industries Stock Drops Double Digits on Mixed Earnings - March 7 at 8:04 PM
Sunshine Heart Appoints Steve Brandt and Matthew E. Likens to Board of DirectorsSunshine Heart Appoints Steve Brandt and Matthew E. Likens to Board of Directors - February 3 at 6:39 AM
Global Congestive Heart Failure (CHF) Treatment Devices Market Analysis & Trends - Industry Forecast to 2025 - Research and MarketsGlobal Congestive Heart Failure (CHF) Treatment Devices Market Analysis & Trends - Industry Forecast to 2025 - Research and Markets - January 28 at 6:56 AM
How Big Is the St. Jude Medical Threat to Abiomed, Inc. Stock?How Big Is the St. Jude Medical Threat to Abiomed, Inc. Stock? - January 4 at 6:31 AM
Winnebago Shares Surge 22% On Grand Design Acquisition, Baird UpgradeWinnebago Shares Surge 22% On Grand Design Acquisition, Baird Upgrade - October 3 at 7:07 PM
Global Artificial Organs Industry - Annual estimates and forecasts 2015 - 2022Global Artificial Organs Industry - Annual estimates and forecasts 2015 - 2022 - September 26 at 7:40 PM

SEC Filings

Thoratec (NASDAQ:THOR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Thoratec (NASDAQ:THOR) Income Statement, Balance Sheet and Cash Flow Statement


Thoratec (NASDAQ THOR) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.